Novo Nordisk partners with Orbis on oral peptide macrocycles
The alliance, potentially worth $1.4 billion, targets macrocyclic oral treatments for cardiometabolic disease.
TR
By Tom Reyes · Markets Editor
Sep 17 11:55 ETSource: BioPharma Dive
The wire
- 01Novo Nordisk signed a collaboration with Orbis worth up to $1.4 billion on macrocycle drug discovery.
- 02Deepens Novo's push into orally available peptide and macrocycle therapeutics beyond injectables.
- 03No candidates or timelines disclosed; upfront versus milestone split unspecified.
From the source
Read at biopharmadive.comNovo partners with Orbis, deepening investment in oral peptide drugs
The potentially $1.4 billion alliance will see the two companies collaborate on “macrocycles” that could yield oral treatments for cardiometabolic diseases.